Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Itulazax

- PMLiVE

ALK-Abello debuts its birch pollen allergy therapy in Germany

Key market for the new product

- PMLiVE

Allergy Tx hit hard as birch pollen product stumbles

Shares in the company went into a steep decline this morning

- PMLiVE

Positive mid-stage trial gives Allergy’s investors some welcome relief

Its grass pollen vaccine showed a “highly significant” dose response

- PMLiVE

ALK-Abello appoints Søren Jelert as CFO

He will be based at the company’s headquarters in Denmark

- PMLiVE

Consilium wins Allergy Therapeutics account

Will advise the firm on international investor relations

- PMLiVE

Merck gets US green light for allergy immunotherapy

Expected to provide a significant boost to company's partner Alk-Abello

- PMLiVE

FDA to review Merck & Co’s allergy immunotherapy

Accepts application for oral tablet to protect against ragweed-based allergies

- PMLiVE

ALK Abello appoints UK managing director

Sean Connor joins from Shire

ABPI London offices

Three new members at ABPI

ALK- Abello, Shionogi and Randox join UK trade body

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links